Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.50−0.17 (-1.59%)
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Summit Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Summit Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$458.43M. For fiscal 2025 it was -$322.93M. The highest annual figure on record is -$35.11M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$322.93M | – |
| FY2024 | Dec 31, 2024 | -$142.11M | – |
| FY2023 | Dec 31, 2023 | -$76.76M | – |
| FY2022 | Dec 31, 2022 | -$41.58M | – |
| FY2021 | Dec 31, 2021 | -$72.59M | – |
| FY2019 | Jan 31, 2019 | -$35.11M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$141.12M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$122.29M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$101.94M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$93.08M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$66.74M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$61.17M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$48.67M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$30.30M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$33.00M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$30.13M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$19.46M | -474.9% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$14.90M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$29.27M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$13.13M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $5.19M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$8.56M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$19.22M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$19.00M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$9.18M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$23.57M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$19.17M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$20.67M | – |
See a number that looks wrong?